Compiling findings from the present study, it is noteworthy that in vivo antitumor promoting activity of TQF was restricted by dosage whereby lower dose of TQF (10 mg/kg) suppressed DMBA/TPA-induced mice skin papilloma; whilst higher dose of TQF (100 mg/kg) was found to potentiate tumor development.
At lower doses whereby the shape-induced advantage is less dominant, charge-induced effects can, however, be used to fine-tune the cellular uptake as a prospective 'secondary' uptake regulator for tight dose control in nanoparticle-based drug formulations.
A modified NRI was used to analyze remission per PMS in patients who remained on every other week dosing, whereby NRI was used for patients with missing data and at the point of moving to weekly dosing.
Treatment responses to irradiation are dose-dependent whereby relatively low doses can cause sterility or prevent development and higher doses cause death.
Dose banding, whereby prescribed chemotherapy doses are rounded up or down to pre-determined standard doses, is a common practice including in the three centres studied.
MPH produced an inverted U dose response whereby moderate doses (1.0 2.0 mg/kg, p.o). significantly improved delayed alternation performance, while higher doses (2.0 3.0 mg/kg, p.o). produced perseverative errors in many animals.
This may simply be a dose effect whereby discriminatory tumour-associated genes are no longer differential in 'low percentage samples' due to low signal.
There was also a possible dose relationship whereby the likelihood of having BD (compared with MDD or no mood disorder) increased with number of pain sites.> -wrap-foot> *Relatove to non-mood disordered comparison group.
Several pheromonal responses in insects and mammals show dose responsivity whereby a stronger pheromonal stimulus evokes a greater response (e.g. Coureaud et al., He et al. and Perna et al. ).
The growth rate of rifampicin populations differed significantly between the two generations (F 1,110) = 53.5, P < 0.001), because of a second-generation dose effect whereby growth in the 2.7% and 0.9% treatments was significantly lower than that in the 0.3% treatments which, in turn, was lower than those in the 0.03% or 0% treatments.
